Cardiol Therapeutics Inc (CRDL)

May 01, 2026

CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill

May 01, 2026

Apr 29, 2026

Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart

Apr 29, 2026

Apr 29, 2026

Phase III Trial Enrollment Reached (75%) for Promising - openPR.com

Apr 29, 2026

Apr 29, 2026

User - The Chronicle-Journal

Apr 29, 2026

Apr 29, 2026

MSN Money - MSN

Apr 29, 2026

Apr 28, 2026

Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics Inc. - Baystreet.ca

Apr 28, 2026

Apr 28, 2026

Stocks in play: Cardiol Therapeutics Inc. - Barchart

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan

Apr 28, 2026

Apr 28, 2026

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - ChartMill

Apr 28, 2026

Apr 28, 2026

Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire

Apr 28, 2026

Apr 27, 2026

Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart

Apr 27, 2026

Apr 27, 2026

Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com

Apr 27, 2026

Apr 23, 2026

Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart

Apr 23, 2026

Apr 23, 2026

Positive Results on MAVERIC Phase III Trial and Published ARCHER - openPR.com

Apr 23, 2026

Apr 23, 2026

CRDL (Cardiol Therapeutics Inc.) Q4 2025 narrower than expected loss lifts shares more than 7 percent higher today.Revenue Diversification - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Is Cardiol (CRDL) stock sensitive to volatility (Drops Sharply) 2026-04-22Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 22, 2026

Metro Q2 2026 Earnings Rise On Margins, Buybacks And Pharmacy Growth - thedeepdive.ca

Apr 22, 2026

Apr 21, 2026

Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network

Apr 21, 2026

Apr 21, 2026

Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year HighHere's Why - MarketBeat

Apr 21, 2026

Apr 20, 2026

CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill

Apr 20, 2026

Apr 19, 2026

Fixing Heart Disease Tied to Sudden Death in Young People | David ElsleyCardiol Therapeutics - thedeepdive.ca

Apr 19, 2026

Apr 18, 2026

Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9%Here's What Happened - MarketBeat

Apr 18, 2026

Apr 15, 2026

Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - MarketBeat

Apr 15, 2026

Apr 14, 2026

Cardiol Therapeutics CEO to discuss drug trials in interview By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 14, 2026

Cardiol Therapeutics CEO to discuss drug trials in interview - Investing.com

Apr 14, 2026

Apr 14, 2026

Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview - TipRanks

Apr 14, 2026

Apr 14, 2026

Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan

Apr 14, 2026

Apr 14, 2026

Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan

Apr 14, 2026

Apr 14, 2026

Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Apr 14, 2026

Apr 13, 2026

$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart

Apr 13, 2026

Apr 13, 2026

$30 Billion Per Year US Heart Failure Market Presents Huge - openPR.com

Apr 13, 2026

Apr 12, 2026

Top Athira Pharma (LONA) Competitors 2026 - MarketBeat

Apr 12, 2026

Apr 12, 2026

Earnings Report: Is Cardiol Therapeutics Inc a cyclical or defensive stock2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn

Apr 12, 2026

Apr 11, 2026

Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail

Apr 11, 2026

Apr 10, 2026

3 Biotech Stocks Surge with Momentum - National Today

Apr 10, 2026

Apr 10, 2026

Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date - Stock Titan

Apr 10, 2026

Apr 10, 2026

Risk Off: Should I trade or invest in Cardiol Therapeutics Inc2026 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Apr 09, 2026

Apr 08, 2026

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail

Apr 08, 2026

Apr 08, 2026

Cardiol Therapeutics Secures Funding Through 2027 Amid Clinical Advancements - AD HOC NEWS

Apr 08, 2026

Apr 07, 2026

CRDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 07, 2026

Apr 07, 2026

Research Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat

Apr 07, 2026

Apr 06, 2026

Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus

Apr 06, 2026

Apr 06, 2026

Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat

Apr 06, 2026

Apr 06, 2026

Cardiol Therapeutics: A 2026 Inflection Point on the Horizon - AD HOC NEWS

Apr 06, 2026

Apr 05, 2026

Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat

Apr 05, 2026